激酶抑制剂-话题@MedSci

#激酶抑制剂#

80篇内容 | 1189人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2039926, encodeId=b3a2203992662, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=AJH：使用基于布鲁顿酪氨酸激酶抑制剂的一线疗法治疗TP53改变的 CLL：回顾性分析, objectType=article, longId=727113, objectId=2ccae2711328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccae2711328, replyNumber=0, likeNumber=60, createdTime=2022-11-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccae2711328, moduleTitle=AJH：使用基于布鲁顿酪氨酸激酶抑制剂的一线疗法治疗TP53改变的 CLL：回顾性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ccae2711328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039928, encodeId=232e2039928e0, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌, objectType=article, longId=729651, objectId=592de2965133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=592de2965133, replyNumber=0, likeNumber=67, createdTime=2023-05-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=592de2965133, moduleTitle=Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=592de2965133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039930, encodeId=c409203993071, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Rheumatology：Janus激酶抑制剂和新型活动性疾病生物标记物在青少年皮肌炎中的长期随访结果, objectType=article, longId=734175, objectId=c505e341758a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c505e341758a, replyNumber=0, likeNumber=63, createdTime=2023-04-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c505e341758a, moduleTitle=Rheumatology：Janus激酶抑制剂和新型活动性疾病生物标记物在青少年皮肌炎中的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c505e341758a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039929, encodeId=d1242039929c2, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=新型 p38 丝裂原活化蛋白激酶抑制剂可逆转缺氧诱导的大鼠肺动脉高压, objectType=article, longId=733923, objectId=b021e339232f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b021e339232f, replyNumber=0, likeNumber=43, createdTime=2023-04-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b021e339232f, moduleTitle=新型 p38 丝裂原活化蛋白激酶抑制剂可逆转缺氧诱导的大鼠肺动脉高压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b021e339232f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039924, encodeId=1b7c203992480, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究, objectType=article, longId=301207, objectId=11cf30120ed4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cf30120ed4, replyNumber=0, likeNumber=46, createdTime=2022-05-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cf30120ed4, moduleTitle=Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cf30120ed4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039922, encodeId=c616203992238, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益, objectType=article, longId=221252, objectId=69a622125247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a622125247, replyNumber=0, likeNumber=50, createdTime=2022-08-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a622125247, moduleTitle=Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a622125247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039925, encodeId=98722039925d1, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle= Ann Med ：用酪氨酸激酶抑制剂治疗的患有慢性期慢性粒细胞白血病的青少年和年轻人的结果, objectType=article, longId=725905, objectId=f05ce2590585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f05ce2590585, replyNumber=0, likeNumber=62, createdTime=2023-02-15, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f05ce2590585, moduleTitle= Ann Med ：用酪氨酸激酶抑制剂治疗的患有慢性期慢性粒细胞白血病的青少年和年轻人的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f05ce2590585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039921, encodeId=4dc720399211b, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果, objectType=article, longId=220644, objectId=1bac22064495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bac22064495, replyNumber=0, likeNumber=48, createdTime=2022-08-15, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bac22064495, moduleTitle=Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bac22064495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039927, encodeId=100a203992e13, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究, objectType=article, longId=727689, objectId=c057e27689e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c057e27689e7, replyNumber=0, likeNumber=48, createdTime=2022-10-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c057e27689e7, moduleTitle=HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c057e27689e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039923, encodeId=8b9720399236e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Cancers：中性粒细胞胞外陷阱在慢性粒细胞白血病中增加，并且受酪氨酸激酶抑制剂的不同影响 , objectType=article, longId=293968, objectId=658129396889, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=658129396889, replyNumber=0, likeNumber=56, createdTime=2022-03-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=658129396889, moduleTitle=Cancers：中性粒细胞胞外陷阱在慢性粒细胞白血病中增加，并且受酪氨酸激酶抑制剂的不同影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=658129396889)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039917, encodeId=ae7e203991eeb, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比, objectType=article, longId=207346, objectId=f9b820e346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9b820e346bb, replyNumber=0, likeNumber=51, createdTime=2021-05-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9b820e346bb, moduleTitle=Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9b820e346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039919, encodeId=e70c20399196f, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=51, createdTime=2021-05-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039912, encodeId=2c9c20399122f, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JAMA Oncology：慢性髓细胞白血病患者停用酪氨酸激酶抑制剂后的预后评估, objectType=article, longId=203471, objectId=188b2034e1e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=188b2034e1e6, replyNumber=0, likeNumber=59, createdTime=2021-10-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=188b2034e1e6, moduleTitle=JAMA Oncology：慢性髓细胞白血病患者停用酪氨酸激酶抑制剂后的预后评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=188b2034e1e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039920, encodeId=be3220399202d, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=44, createdTime=2021-07-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039918, encodeId=1cc82039918b8, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, objectType=article, longId=209220, objectId=b2172092201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2172092201a, replyNumber=0, likeNumber=44, createdTime=2021-06-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2172092201a, moduleTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2172092201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039911, encodeId=ca8c2039911ad, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=NEJM：Janus激酶抑制剂在小儿Aicardi-Goutieres综合征中的作用, objectType=article, longId=200383, objectId=b6972003833b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6972003833b, replyNumber=0, likeNumber=37, createdTime=2020-10-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6972003833b, moduleTitle=NEJM：Janus激酶抑制剂在小儿Aicardi-Goutieres综合征中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6972003833b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039915, encodeId=27782039915c0, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌, objectType=article, longId=205516, objectId=f6672055161a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6672055161a, replyNumber=0, likeNumber=54, createdTime=2021-03-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6672055161a, moduleTitle=J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6672055161a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039914, encodeId=4f9c2039914c4, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：Bruton酪氨酸激酶抑制剂会不会影响疫苗接种的效果？, objectType=article, longId=204130, objectId=4c7620413018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c7620413018, replyNumber=0, likeNumber=59, createdTime=2020-12-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c7620413018, moduleTitle=Blood：Bruton酪氨酸激酶抑制剂会不会影响疫苗接种的效果？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c7620413018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039916, encodeId=ad2d2039916ed, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析, objectType=article, longId=206381, objectId=297020638150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297020638150, replyNumber=0, likeNumber=72, createdTime=2021-05-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297020638150, moduleTitle=Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297020638150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039909, encodeId=9b3b203990939, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=49, createdTime=2021-03-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激酶抑制剂

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

AJH：使用基于布鲁顿酪氨酸激酶抑制剂的一线疗法治疗TP53改变的 CLL：回顾性分析

2022-11-14

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌

2023-05-20

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Rheumatology：Janus激酶抑制剂和新型活动性疾病生物标记物在青少年皮肌炎中的长期随访结果

2023-04-07

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

新型 p38 丝裂原活化蛋白激酶抑制剂可逆转缺氧诱导的大鼠肺动脉高压

2023-04-02

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究

2022-05-07

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益

2022-08-16

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Ann Med ：用酪氨酸激酶抑制剂治疗的患有慢性期慢性粒细胞白血病的青少年和年轻人的结果

2023-02-15

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果

2022-08-15

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究

2022-10-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Cancers：中性粒细胞胞外陷阱在慢性粒细胞白血病中增加，并且受酪氨酸激酶抑制剂的不同影响

2022-03-25

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比

2021-05-06

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-05-19

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JAMA Oncology：慢性髓细胞白血病患者停用酪氨酸激酶抑制剂后的预后评估

2021-10-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-07-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！

2021-06-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

NEJM：Janus激酶抑制剂在小儿Aicardi-Goutieres综合征中的作用

2020-10-09

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌

2021-03-21

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：Bruton酪氨酸激酶抑制剂会不会影响疫苗接种的效果？

2020-12-26

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析

2021-05-20

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2021-03-10

科室
- - 订阅+
  - 更多科室
工具
服务